Vaniprevir (MK-7009) is a novel macrocyclic hepatitis C virus (HCV) NS3/4a protease inhibitor with an attractive preclinical profile including high in vitro potency, significant liver exposure upon oral dosing and efficacy in a chimpanzee model of chronic HCV infection. The design and discovery of vaniprevir, as well as the next-generation HCV NS3/4a protease inhibitor MK-5172, will be presented in addition to selected clinical data for these compounds.

Discovery of vaniprevir (MK-7009) and MK-5172: Macrocyclic HCV NS3/4a protease inhibitors

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.